Glen Clova Scientific has moved its R&D operations to the James Hutton Institute in Dundee, Scotland, following a period of growth in both its research activities and operational team.

The company, which focuses on immunology and inflammation drug development, was previously based at the University of Dundee’s School of Life Sciences.

According to Glen Clova Scientific, the relocation supports its work on a pipeline of next-generation advanced biologics and the licensing of its platform for single-step production of virus-like particles (VLPs). Since securing funding last year, the company reports it has expanded its internal development programs and collaboration network.

Dr. John Foerster, founder and chief scientific officer, said the move will provide access to larger laboratory facilities needed to advance immune-dermatology projects.

“We are grateful to the University of Dundee, and specifically the members of the School of Life Sciences, for their support during the early stages of the company’s development,” Foerster said.

“We are excited to expand our pipeline and network now that we have moved to larger facilities, and appreciate the welcome we have received from the James Hutton Institute.”

Alasdair Cox, head of operations at the James Hutton Institute, said Glen Clova Scientific’s arrival adds to the expertise on its Invergowrie campus.

“The diverse expertise offered by all of our campus partners provides opportunities for collaboration, innovation, and knowledge exchange. We look forward to learning more about Glen Clova Scientific’s work as they settle into their new home,” Cox said.